Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Hemostemix V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc is a clinical-stage biotechnology company. The company's principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions. Its technology platform for developing autologous cell therapies is for the treatment of vascular diseases. The group's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Caps on Russian oil not enough for the TSX
Following a new round of restrictions announced at a meeting of G7 leaders capping prices on the sale and purchase of Russian oil, Canada’s commodity-heavy main stock index came out of the gate... read article.

$HMTXF about to issue the global field use license of NCP-01

Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous stem cell technology to treat central and peripheral nervous system diseases. Such as Neuropathic pain...read more

$HEM announcement related to the Stock Options Grant

Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common...read more

$HMTXF a praiseworthy stock multiplying in heavily

$HMTXF has been on quite an impressive venture, the stock is seen to have much potential by the investors and is a worthy investment, shares are trading at $0.1960 with a 0.20% jump in value.  rate and reply

$HEM Market Insight

Hemostemix is a clinical-stage biotechnology company trading in TSX-V with ticker symbol $HEM is currently sitting at $0.255 with volume of $8.62K+.  rate and reply

Hemostemix Inc. Market Graph

Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.  rate and reply

$HEM Stock Analysis and Evaluation

Hemostemix Inc. is an emerging biotechnology company listed on TSX-V with the ticker symbol $HEM traded today at price of $0.255 per share.  rate and reply

$HEM announced amalgamation of an entirely owned subsidiary

The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem...read more

$HEM grants worldwide field license to PreCerv Inc.

Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central...read more

$HEM announced the addition of a wholly owned subsidiary

Hemostemix recently announced the incorporation of PreCerv Inc. (A wholly owned subsidiary of Hemostemix). Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous...read more

CEO Hemostemix highlighted the mounting demand of $HEM.

Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the...read more

$HEM market cap shoot up to $17 Million

$HEM have developed and established a firm market cap which has been on the rise steadily since the listing of the stock on TSX-V, currently the cap valuation is $17.404Million.  rate and reply

Data audit efficiently executed, results came out to be auth

Hemostemix have been handed back its intellectual property consisting of all the clinical trial data of ACP-01 which was long unlawfully held by Accudata and Aspire Health Science, the data audit post...read more

$HEM perfect patent record and universal acknowledgement

$HEM owns a total of 91 patents in 5 different categories falling under 25 jurisdictions and also been a recipient of world economic forum technology award.  rate and reply

Hemostemix Inc. (TSXV: HEM)(OTC: HMTXF) The Numero Uno Stock

www.marketwatch.com/.../hemostemix-inc-tsxv-hem-otc-hmtxf-the-numero-uno-stock-investment-in-the-game-2022-06-28    rate and reply

The big green blob on graph. Buying by insiders !!

https://m.canadianinsider.com/node/7?menu_tickersearch=THC+%7C+THC+Biomed+Intl  rate and reply

I am glad i bought and sold made profit. Reinvested in THC

Financials due in a couple of days. I think their biscuits are selling like hot cakes . A lot of buying buy the CEO and CFO lately. Looks like a big green blob of insider buying on the graph. DYODD  rate and reply
@ the Bell: The worst 1st half for stocks in decades
Gains in crude prices pushed futures for Canada’s main stock index higher on Monday although recession fears continued to weigh on sentiment.Canada’s competition bureau said that Rogers Communicat... read article.

$HMTXF outstanding shares and public float summary

$HMTXF has successfully offered and issued an aggregate of 68.2 Million to the shareholders globally in terms of outstanding shares, and a total of 19.34 Million shares are available for the general...read more

$HMTXF outstanding shares and public float summary

$HMTXF has successfully offered and issued an aggregate of 68.2 Million to the shareholders globally in terms of outstanding shares, and a total of 19.34 Million shares are available for the general...read more

Hemostemix achieves lawful possession of all its missing int

All the intellectual data including all phase 2 clinical trial data, all the historical data from hemostemix Israel, and the randomized table required to analyze North-American and South-African ACP...read more

$HEM grants worldwide field license to PreCerv Inc.

Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central...read more